Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
PLAINSBORO, N.J., March 16, 2017 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a global leader in medical technology, announces the launch of its new CUSA® Clarity ultrasonic tissue ablation platform designed to deliver an innovative, integrated system for enhanced performance and long-lasting surgeon comfort in neurosurgical cases.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8b5375f4-19a1-46ed-9d75-880d2ddd6006
Integra’s CUSA® Clarity was engineered to maximize surgical performance for surgeons, staff and patients through a system that provides power, precision and comfort for complex neurosurgery. The unique CUSA® Clarity system is the only ultrasonic tissue ablation system that combines a tough tissue tip, continuous tissue contact, a precision and ergonomic handpiece, and adaptive power all in one system. These four integrated components provide a greater than 50 percent increase in fibrous tissue removal rate over the CUSA® Excel+ system.
The next generation CUSA® Clarity also features an improved handpiece design with a focus on sustained comfort and precision as well as a sleek new console design with an intuitive touchscreen and CUSA Quick Connect™ cartridge and tubing set to streamline operating room setup and workflow. The system is a scalable platform to support future enhancements.
“This latest innovation in tissue ablation is a result of Integra’s focus on designing and developing an advanced system that meets the surgeons’ needs for enhanced surgical performance, especially for longer and tougher cases like fibrous tissue removal,” says Dan Reuvers, president of the Specialty Surgical Solutions division for Integra. “We’re delighted to bring this new system to a demanding surgical environment that enhances patient care.”
The CUSA® Clarity was developed with extensive feedback from over 150 touchpoints worldwide. CUSA® Clarity is currently available for sale in the U.S. and select EU countries (contact your representative for more information). For U.S. customers, a 98.5% uptime guarantee is available with the addition of Integra’s IntegraLink™ Protection Plus program. CUSA® Clarity was cleared by the U.S. Food and Drug Administration and has obtained CE Mark approval. For more information and further indications for use, visit our website for U.S. customers.
About Integra
Integra LifeSciences Holdings Corporation, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.
CONTACT: Integra LifeSciences Holdings Corporation Investors Angela Steinway 609-936-2268 [email protected] Michael Beaulieu 609-750-2827 [email protected] Media Laurene Isip 609-750-7984 [email protected]
